Intra-myometrial injection of carbetocin versus vasopressin for reduction of blood loss in myomectomy operations

Abstract

Background: There are various contemporary therapies for uterine fibroids, but surgical resection—including hysterectomy and myomectomy—remains the primary method. This study compared the effectiveness of intramyometrial carbetocin injection versus vasopressin for reducing blood loss in myomectomy instances.Methods: This randomized, comparative clinical trial was performed on 60 female patients undergoing myomectomy with uterine fibroids, abnormal vaginal bleeding, chronic pelvic pain, pressure symptoms, or reproductive abnormalities and pre-operative hemoglobin levels > 10 g/dL. Three identical groups of patients were formed (N=20): Control group: No medications. Carbetocin group: Using 100 µg carbetocin. vasopressin group: using 20 units vasopressin.Results: In comparison to the other two groups, controls (881.25 ml) experienced a significant rise in overall blood loss (760 and 698 ml in the carbetocin and vasopressin groups respectively). Only two cases—one each in the carbetocin and vasopressin groups—required hysterectomy. Hemoglobin and hematocrit levels were significantly less in control group (9.15 gm/dl) than in the two treatment groups (9.61 and 10.05 gm/dl for carbetocin and vasopressin, respectively). Conclusions: Both vasopressin and carbetocin are safe and efficacious in decreasing bleeding after myomectomy.